Security
Annexon, Inc. Common Stock · ANNX
ANNXNASDAQCommon stockCurrentCIK 1528115Updated Oct 6, 2026
ANNX price & chart
Loading TradingView…
NASDAQ:ANNX on TradingView ↗About the company
Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
In the news
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition · Other Events
Items 2.02, 8.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
Other Events
Items 8.01, 9.01
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Other Events
Items 1.01, 2.03, 8.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 229,142,000Source | 378,776,000Source | 246,068,000Source | 264,573,000Source | 406,085,000Source | 262,888,000Source | 303,027,000Source | 304,069,000Source | 277,571,000Source | 350,071,000Source | 297,674,000Source | 285,096,000Source |
| Property, Plant and Equipment, NetUSD | 11,152,000Source | 13,169,000Source | 9,675,000Source | 11,650,000Source | 13,702,000Source | 10,107,000Source | 12,190,000Source | 14,235,000Source | 10,617,000Source | 12,638,000Source | 14,773,000Source | 16,838,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 139,419,000Source | 79,540,000Source | 199,270,000Source | 132,288,000Source | 157,304,000Source | 175,208,000Source | 97,122,000Source | 151,941,000Source | 162,051,000Source | 49,498,000Source | 225,110,000Source | 140,020,000Source |
| Assets, CurrentUSD | 192,822,000Source | 344,292,000Source | 212,757,000Source | 230,620,000Source | 373,969,000Source | 228,266,000Source | 268,162,000Source | 270,740,000Source | 242,191,000Source | 316,461,000Source | 263,860,000Source | 248,098,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,101,000Source | 4,176,000Source | 3,514,000Source | 3,603,000Source | 5,270,000Source | 3,241,000Source | 4,466,000Source | 5,792,000Source | 3,846,000Source | 4,444,000Source | 4,144,000Source | 5,441,000Source |
| Operating Lease, Right-of-Use AssetUSD | 15,587,000Source | 17,050,000Source | 14,333,000Source | 15,974,000Source | 17,382,000Source | 14,767,000Source | 16,346,000Source | 17,701,000Source | 15,185,000Source | 16,705,000Source | 18,009,000Source | 19,128,000Source |
| Other Assets, NoncurrentUSD | 8,549,000Source | 3,233,000Source | 8,271,000Source | 5,297,000Source | — | 8,716,000Source | 5,297,000Source | 361,000Source | 8,546,000Source | 3,235,000Source | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 67,700,000Source | 47,216,000Source | 60,007,000Source | 65,556,000Source | 45,006,000Source | 58,355,000Source | 59,239,000Source | 41,664,000Source | 65,923,000Source | 56,966,000Source | 47,118,000Source | 53,902,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 115,000Source | 106,000Source | 175,000Source | 110,000Source | 106,000Source | 162,000Source | 109,000Source | 90,000Source | 149,000Source | 109,000Source | 78,000Source | 48,000Source |
| Additional Paid in CapitalUSD | 1,030,536,000Source | 993,486,000Source | 1,202,847,000Source | 1,013,211,000Source | 988,347,000Source | 1,165,983,000Source | 1,008,825,000Source | 860,092,000Source | 1,128,917,000Source | 1,003,685,000Source | 823,029,000Source | 669,780,000Source |
| Retained Earnings (Accumulated Deficit)USD | -869,133,000Source | -662,109,000Source | -1,016,879,000Source | -814,211,000Source | -627,285,000Source | -961,531,000Source | -765,055,000Source | -597,675,000Source | -917,389,000Source | -710,699,000Source | -572,499,000Source | -438,262,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -76,000Source | 77,000Source | -82,000Source | -93,000Source | -89,000Source | -81,000Source | -91,000Source | -102,000Source | -29,000Source | 10,000Source | -52,000Source | -372,000Source |
| Stockholders' Equity Attributable to ParentUSD | 161,442,000Source | 331,560,000Source | 186,061,000Source | 199,017,000Source | 361,079,000Source | 204,533,000Source | 243,788,000Source | 262,405,000Source | 211,648,000Source | 293,105,000Source | 250,556,000Source | 231,194,000Source |
| Liabilities and EquityUSD | 229,142,000Source | 378,776,000Source | 246,068,000Source | 264,573,000Source | 406,085,000Source | 262,888,000Source | 303,027,000Source | 304,069,000Source | 277,571,000Source | 350,071,000Source | 297,674,000Source | 285,096,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 43,580,000Source | 20,046,000Source | 38,482,000Source | 40,642,000Source | 17,148,000Source | 35,937,000Source | 33,547,000Source | 13,133,000Source | 42,630,000Source | 30,512,000Source | 17,928,000Source | 22,360,000Source |
| Operating Lease, Liability, CurrentUSD | 2,818,000Source | 2,437,000Source | 3,126,000Source | 2,716,000Source | 2,345,000Source | 3,016,000Source | 2,616,000Source | 2,254,000Source | 2,908,000Source | 2,518,000Source | 2,165,000Source | 1,316,000Source |
| Accounts Payable, CurrentUSD | 18,219,000Source | 6,748,000Source | 15,731,000Source | 11,515,000Source | 4,126,000Source | 17,529,000Source | 10,437,000Source | 3,972,000Source | 14,931,000Source | 10,426,000Source | 5,487,000Source | 7,416,000Source |
| Operating Lease, Liability, NoncurrentUSD | 24,120,000Source | 27,170,000Source | 21,525,000Source | 24,914,000Source | 27,858,000Source | 22,418,000Source | 25,692,000Source | 28,531,000Source | 23,293,000Source | 26,454,000Source | 29,190,000Source | 31,542,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | — | — | — | 10,657,000Source | — | — | 6,857,000Source | — | — | 10,235,000Source | 13,448,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 188,700,000Source | 340,100,000Source | 209,200,000Source | 227,000,000Source | 368,700,000Source | 225,000,000Source | 263,700,000Source | 264,900,000Source | 238,300,000Source | 312,000,000Source | 259,700,000Source | 242,700,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 539,000Source | 537,000Source | 2,166,000Source | 2,150,000Source | 2,148,000Source | 2,106,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | 4,813,000Source | 4,205,000Source | 4,156,000Source | 5,078,000Source | 16,423,000Source | 19,433,000Source | 18,183,000Source | 18,516,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 2,151,000Source | -31,000Source | 4,491,000Source | 4,936,000Source | -2,077,000Source | -287,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -46,796,000Source | -50,055,000Source | -186,356,000Source | -118,006,000Source | -121,142,000Source | -116,309,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 27,056,000Source | 97,620,000Source | 190,052,000Source | -218,797,000Source | 70,703,000Source | 58,443,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 74,000Source | 137,000Source | 15,000Source | 193,000Source | 6,526,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 32,896,000Source | 59,000Source | 108,855,000Source | 161,206,000Source | 135,524,000Source | 122,908,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 140,451,000Source | 80,572,000Source | 200,302,000Source | 133,320,000Source | 176,240,000Source | 98,154,000Source | 163,083,000Source | 50,530,000Source | 226,142,000Source | 141,052,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 1,000Source | 0Source | 2,000Source | -15,000Source | 5,000Source | 1,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 3,835,000Source | 4,609,000Source | 4,813,000Source | 4,205,000Source | 4,156,000Source | 5,078,000Source | 16,423,000Source | 19,433,000Source | 18,183,000Source | 18,516,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 188,700,000Source | 340,100,000Source | 209,200,000Source | 227,000,000Source | 225,000,000Source | 263,700,000Source | 238,300,000Source | 312,000,000Source | 259,700,000Source | 242,700,000Source |
| DepreciationUSD | — | — | 500,000Source | 500,000Source | 540,000Source | 540,000Source | 500,000Source | 500,000Source | 2,200,000Source | 2,200,000Source | 2,100,000Source | 2,100,000Source |
| General and Administrative ExpenseUSD | — | — | 7,318,000Source | 9,337,000Source | 10,637,000Source | 7,566,000Source | 10,267,000Source | 9,226,000Source | 31,709,000Source | 34,625,000Source | 29,967,000Source | 33,098,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -54,922,000Source | -34,824,000Source | -55,348,000Source | -49,156,000Source | -44,142,000Source | -54,356,000Source | -206,690,000Source | -138,200,000Source | -134,237,000Source | -141,947,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -54,922,000Source | -34,824,000Source | -55,348,000Source | -51,013,000Source | — | — | -208,547,000Source | — | — | -141,947,000Source |
| Operating ExpensesUSD | — | — | 57,018,000Source | 39,442,000Source | 57,227,000Source | 51,726,000Source | 46,053,000Source | 57,405,000Source | 216,407,000Source | 154,073,000Source | 143,723,000Source | 145,599,000Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | 936,000Source | 3,000Source | 1,619,000Source | 2,259,000Source | 555,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 33,603,000Source | 0Source | 28,488,000Source | 44,371,000Source | — | — |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | 33,000,000Source | 159,500,000Source | 402,400,000Source | 365,150,000Source | 178,984,000Source | 178,166,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 229,000Source | 62,000Source | 461,000Source | 1,232,000Source | 90,000Source | 80,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -57,018,000Source | -39,442,000Source | -57,227,000Source | -51,726,000Source | -46,053,000Source | -57,405,000Source | -216,407,000Source | -154,073,000Source | -143,723,000Source | -145,599,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -206,690,000Source | 138,200,000Source | 134,237,000Source | 141,947,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -54,922,000Source | -34,824,000Source | -55,348,000Source | -49,156,000Source | -44,142,000Source | -54,356,000Source | -206,690,000Source | -138,200,000Source | -134,237,000Source | -141,947,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.37Source | -0.25Source | -0.28Source | -0.34Source | -0.23Source | -0.37Source | -1.34Source | -1.01Source | -1.77Source | -2.6Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.37Source | -0.25Source | -0.28Source | -0.34Source | -0.23Source | -0.37Source | -1.34Source | -1.01Source | -1.77Source | -2.6Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 149,123,701Source | 139,933,019Source | 201,003,269Source | 148,320,803Source | 194,200,100Source | 148,108,809Source | 155,105,832Source | 137,404,145Source | 75,673,081Source | 54,673,572Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 149,123,701Source | 139,933,019Source | 201,003,269Source | 148,320,803Source | 194,200,100Source | 148,108,809Source | 155,105,832Source | 137,404,145Source | 75,673,081Source | 54,673,572Source |
| Additional Financial Items | ||||||||||||
| Common Stock, Dividends, Per Share, DeclaredUSD per share | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 7,318,000Source | 9,337,000Source | 10,637,000Source | 7,566,000Source | 10,267,000Source | 9,226,000Source | 31,709,000Source | 34,625,000Source | 29,967,000Source | 33,098,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -206,681,000Source | 138,193,000Source | 134,233,000Source | 141,939,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -54,922,000Source | -34,824,000Source | -55,348,000Source | -51,013,000Source | — | — | -208,547,000Source | — | — | -141,947,000Source |
| Operating ExpensesUSD | — | — | 57,018,000Source | 39,442,000Source | 57,227,000Source | 51,726,000Source | 46,053,000Source | 57,405,000Source | 216,407,000Source | 154,073,000Source | 143,723,000Source | 145,599,000Source |
| Research and Development ExpenseUSD | — | — | 49,700,000Source | 30,105,000Source | 46,590,000Source | 44,160,000Source | 35,786,000Source | 48,179,000Source | 184,698,000Source | 119,448,000Source | 113,756,000Source | 112,501,000Source |
Offerings
Registration 333-294758
Filing attachments
d119960dex991.htm · 8-K · 2026-08-12
EX-99.1 2 d119960dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 2026 Vonaprument Phase 3 GA Program Expanded with Month 15 / 24 Dual Primary Endpoint Strategy and Launch of Open-L…
Read attachment ↗d119960dex992.htm · 8-K · 2026-08-12
EX-99.2 3 d119960dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study Strong Execution of Well-Powered ARCHER II Trial Reaffirms Month 15 Primary Endpoint on Track for Q4 2026 Strategic Expansion Underscores Vonaprument’s Best-in-Class Potential as the First and Only Treatment for Vision Preservation in GA B…
Read attachment ↗d130710dex991.htm · 8-K · 2026-08-10
EX-99.1 2 d130710dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors Over Four Decades of Clinical, Scientific and Corporate Leadership Advancing Innovation in Retinal Disease BRISBANE, Calif., August 10, 2026 - Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory di…
Read attachment ↗d159969dex991.htm · 8-K · 2026-08-06
EX-99.1 2 d159969dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week Early Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previously Demonstrated in Phase 3 and Real-World Evidence Studies Potential to Become the First Approved Targeted Therapy to Treat GBS Worldwide, Addressing the Si…
Read attachment ↗d113783dex991.htm · 8-K · 2026-07-30
EX-99.1 3 d113783dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance Expands Financial Capacity as Vonaprument and Tanruprubart Programs Advance Toward Registration BRISBANE, Calif., July 30, 2026 - Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, today a…
Read attachment ↗annx-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 annx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Redefine Vision Preservation in GA Tanruprubart EU Marketing Authorization Application (MAA) Under Review as the Potentially First Targeted Therapy for Guillain-Barré Syndrome (GBS); Biologics License Applic…
Read attachment ↗